Search Results for ""
Issue 09/02/2021Launch Price Tracker
News 09/01/2021Senate Moves Forward with $1.2 trillion Infrastructure Bill, Includes Funding Offset from Bach’s Drug Vial Waste Research
The infrastructure bill includes a drug waste provision from the Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act, which requires manufacturers to rebate the amount wasted back to CMS. An estimated $3 billion over 10 years can be recouped and invested in roads, bridges, and other infrastructure initiatives.
Impact Story 09/01/2021Savings from drug waste funds a $1.2 trillion infrastructure bill
Research 08/18/2021Production Plus Profit Pricing (P-quad) FAQ
Research 08/13/2021What A Waste! The National Academy Of Medicine’s Report On Oversized Vials Of Expensive Drugs
Why Congress should not follow the National Academy of Science, Engineering, and Medicine’s recommendation to remove the JW modifier.
Research 08/13/2021Medicare Must Study Unproven, Expensive Alzheimer’s Drug
Medicare cannot indiscriminately cover the cost of Aduhelm for the treatment of Alzheimer's disease without first evaluating whether it truly works.
Research 08/13/2021Value-Based Management of Specialty Drugs: Practical Considerations and Implications for Pharmacy
Not all approaches are suited to meeting policy makers and health plans’ goals of managing specialty drugs based on their value. Researchers conducted a qualitative study with Blue Cross Blue Shield plans interested in implementing value-based specialty pharmacy management to observe the plans’ objectives, strategies, and factors influencing their ability to execute on these strategies.
Research 04/09/2021Trump's Drug-Pricing Ideas Would Cost Taxpayers a Bundle
Meanwhile, pharmaceutical companies would stand to make a lot more money.
Research 04/09/2021We can't tackle the pandemic without figuring out which Covid-19 vaccines work the best
There may be several Covid-19 vaccines by winter, but there will also need to be a study comparing the viruses to one another as part of rolling out widespread vaccination.
Research 04/09/2021Instead of debating 'first-shot' vs 'set-aside' vaccine approaches, hospitals' study should compare them
Hospitals could start studies of their own employees to answer important questions, including whether the first-shot approach has downsides when compared to the set-aside strategy.
Research 04/09/2021After 4 Years of Trump, Medicare and Medicaid Badly Need Attention
Many promising ideas won't work as expected, and that's all the more reason for CMS to evaluate how medical care is delivered to its patients.
Research 04/09/2021CMS's Proposed Medicaid Best Price Loophole for Value-Based Purchasing of Drugs
The administration has proposed a loophole in the Medicaid Best Price rules that would dismiss linking the drug's effectiveness to its price.
Research 04/09/2021The Science on Coronavirus is Topsy-Turvy. That's Fine.
Urgency demands patience, because advancement is always a product of missteps.
News 04/09/2021CMS Announces Delay of MCIT Final Rule
CMS delays the effective date of MCIT rule on "breakthrough" designation after concerns raised by physicians, including Peter Bach.
Research 03/15/2021The Drugs at the Heart of Our Pricing Crisis
The US drug pricing system is broken, but not irreparable. For large-molecule biologic drugs, enter: Production Plus Profit Pricing (P-quad, pronounced like Ahab's seagoing vessel).
Research 03/15/2021Biosimilars: Market Changes do not equal policy success
Numerous articles and reports have trumpeted biosimilar market growth, but it's critical we do not lose sight of the sole objective for creating the biosimilar market: to reduce the cost of older biologic drugs for society and taxpayers.
News 03/15/2021Curbing Biologic Drug Spending with P-quad
Peter Bach and Mark Trusheim's latest drug pricing idea: Have biologic innovators lower prices to "cost" plus a fixed (and generous) profit margin. The result? Huge financial savings for everyone.
Research 03/15/2021Ethics of Clinical Trials to Evaluate Biosimilars
Biosimilars require extensive, expensive, and time-consuming human testing prior to market entry, a process vastly different than generics. So why are we still doing them?
Research 03/15/2021Bottom-Up Pricing Estimate for P-quad
How much would biologic drugs cost under P-quad pricing? Two approaches to estimating fully loaded costs plus a profit (10% and 20% examined) suggest net discounts from current prices would be at least 65% to 75%
Research 03/15/2021Modeling P-quad
The Drug Pricing Lab engaged Milliman to conduct an independent analysis of the Production Plus Profit Pricing (P-quad) policy proposal. The Milliman analysis estimates the projected spending on U.S. biologic and biosimilar drugs under a referent scenario where there is no biosimilar entry or competition, the existing ‘status quo’ scenario under the current biosimilar environment, and the Drug Pricing Lab’s P-quad policy proposal.
This report was commissioned by Drug Pricing Lab.
This report was commissioned by Drug Pricing Lab.
Research 03/02/2021COVID-19 Reduced Average Life Expectancy of Americans by Five Days, Not One Year
The CDC made a mistake.
Research 01/13/2021Priceless Knowledge: Attitudes and Awareness Around Drug Pricing Among US Medical Students
Medical students' education covers topics spanning health, disease, and treatment, but what about drug pricing and their role as prescribers?
Impact Story 01/06/2021How a “Netflix Model” Can Help States Pay for Hepatitis C Treatment
Impact Story 11/12/2020Adding Cost to the Equation: The Case of Zaltrap
Impact Story 11/12/2020Testifying Before the US Senate Committee on Finance
Impact Story 11/12/2020PR Week’s 2020 Health Influencer 50 List
Issue 11/02/2020Profitability over Public Health and Innovation
Issue 11/02/2020Supply Chain Economics Favor Higher Cost Drugs
Issue 11/02/2020Abuses of Government Programs and Regulations
Person 10/29/2020Peter B. Bach, MD, MAPP
Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
No Results Found